Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis

• Main Authors: Kenneth L Clark (Author), Stephen A Hughes (Author), Pallav Bulsara (Author), Jill Coates (Author), Kitty Moores (Author), Joel Parry (Author), Michael Carr (Author), Ruth J Mayer (Author), Paul Wilson (Author), Chris Gruenloh (Author), Daren Levin (Author), Jill Darton (Author), Wolf-Michael Weber (Author), Katja Sobczak (Author), Deborah R Gill (Author), Stephen C Hyde (Author), Lee A Davies (Author), Ian A Pringle (Author), Stephanie G Sumner-Jones (Author), Vasant Jadhav (Author), Sharon Jamison (Author), Walter R Strapps (Author), Victoria Pickering (Author), Mark R Edbrooke (Author)
• Format: Book
• Published: Elsevier, 2013-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Lung pathology in cystic fibrosis is linked to dehydration of the airways epithelial surface which in part results from inappropriately raised sodium reabsorption through the epithelial sodium channel (ENaC). To identify a small-interfering RNA (siRNA) which selectively inhibits ENaC expression, che...